Loss of exclusivityJuly 2042latest FDA-listed patent expiry
CompanyKadmon →See this company's full patent-cliff portfolio
Drug detail
Brand name
REZUROCK
Active ingredient
BELUMOSUDIL MESYLATE
Strength
EQ 200MG BASE
Dosage form
TABLET
Route
ORAL
Modality
Small molecule
FDA approval
July 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
12097202
July 2042
use U-4014
11311541
April 2035
use U-3369
8357693
June 2034
substance, product
10183931
October 2033
use U-3246
10696660
October 2033
use U-3246
Regulatory exclusivity
Code
Expires
ODE-362
July 2028
NCE
July 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.